Moreover, given the crucial role of PlGF/VEGFR-1 axis in inflammation, neovascularization, and tumor aggressiveness, the use of aflibercept could be helpful to target both proangiogenic factors and the inflammatory cells surrounding the tumor microenvironment. Here, FLT1 is linked to neoplasm.